A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
NCT ID: NCT00721045
Last Updated: 2020-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2008-08-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
NCT01781390
Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
NCT00555828
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
NCT02032004
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
NCT05925608
A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
NCT02467387
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This will be a single-blinded, dose-escalation, cohort study in 60 subjects allocated sequentially to 1 of 3 cohorts A, B, or C. Forty-five subjects will be randomized to receive transendocardial delivery of MPC treatment, and 15 subjects will be randomized to receive standard-of-care treatment without MPC administration. The fifteen subjects randomized to receive standard of care without needle injection will serve as the study's control population and will undergo mock mapping and verbal injection scripts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1
15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
Mesenchymal Precursor Cells (MPCs)
25 M allogeneic MPCs by transendocardial injection and mapping.
A2
5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
standard-of-care treatment with mock mapping and injection procedures.
Mock
B1
15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
Mesenchymal Precursor Cells (MPCs)
75 M allogeneic MPCs by transendocardial injection and mapping.
B2
5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
standard-of-care treatment with mock mapping and injection procedures.
Mock
C1
15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
Mesenchymal Precursor Cells (MPCs)
150 M allogeneic MPCs by transendocardial injection
C2
5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
standard-of-care treatment with mock mapping and injection procedures.
Mock
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mesenchymal Precursor Cells (MPCs)
25 M allogeneic MPCs by transendocardial injection and mapping.
Mesenchymal Precursor Cells (MPCs)
75 M allogeneic MPCs by transendocardial injection and mapping.
Mesenchymal Precursor Cells (MPCs)
150 M allogeneic MPCs by transendocardial injection
standard-of-care treatment with mock mapping and injection procedures.
Mock
standard-of-care treatment with mock mapping and injection procedures.
Mock
standard-of-care treatment with mock mapping and injection procedures.
Mock
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \>20 and \<80.
3. Cardiomyopathy of ischemic or idiopathic etiology.
4. Subject is not a candidate for either percutaneous intervention or cardiac surgery as determined by both an interventional cardiologist and a cardiac surgeon.
5. LVEF (Left ventricular ejection fraction) \< 40% via 2-D Echocardiogram within 28 days of study procedure.
6. On stable maximal, tolerable dosages of heart failure therapies including betablockers,ace inhibitors and/or diuretics with no interruption or change in medical therapy for at least 28 days prior to study enrollment.
7. Left Ventricle wall thickness ≥ 8mm at target site by echo within 28 days of study procedure.
8. If the subject or partner is of childbearing potential, he or she must be willing to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening and for a period of at least 16 weeks after procedure.
9. Female subjects of childbearing potential must have a negative serum pregnancy test at screening.
10. Willing and able to understand, sign, and date the Informed Consent Form (ICF).
11. Must be willing to return for required follow-up visits.
12. Must be able to follow postoperative management program.
Exclusion Criteria
2. Discharge of subject's ICD within 28 days of study procedure.
3. Sustained Ventricular Tachycardia as demonstrated by QRS complexes wider than 120 msec, lasting \>30 secs, and \>100 bpm documented in screening ECG or 24 hour Holter monitoring.
4. Unstable angina.
5. LV thrombus by echocardiogram or angiogram with 28 days prior to and up to the time of cell injection.
6. Aortic stenosis as determined by echocardiography as valve area less than 1 cm2 that prohibits NOGA catheter access to LV.
7. Cardiogenic shock defined as the need for intravenous inotropic support, an intraaortic balloon pump, or mechanical circulatory support at the time of cell injections.
8. Chronic AF or AF at the time of cell injections.
9. Unprotected left main coronary artery disease \>50%.
10. Ischemic or hemorrhagic stroke as diagnosed by CT/MRI events within the last 3 months prior to enrollment.
11. Bleeding diathesis disorder such as abnormal coagulation profile precluding performing of mapping/injection procedure.
12. Serum glucose level \> 400 mg/dl within 28 days of study procedure.
13. Serum glucose level 300 to 400 mg/dl and presence of urine ketones within 28 days of study procedure.
14. Creatinine level ≥ 2.5 mg/dL within 28 days of study procedure.
15. Hematocrit ≤ 32% within 28 days of study procedure.
16. White Blood Cell count \> 12 x 106/mm3 within 28 days of study procedure.
17. Platelet count ≤100 x106/mm3 within 28 days of study procedure.
18. Total bilirubin \>3 mg/dL, albumin \<2.8 g/dL, aspartate aminotransferase (AST) ≥ 2.5x the upper limit of normal, gamma glutamyltranspeptidase (GGT) ≥ 1.5x the upper limit of normal within 28 days of study procedure.
19. Presence of ≥ 20% anti-HLA antibody titers and/or having antibody specificities to donor HLA antigens.
20. A known hypersensitivity to dimethyl sulfoxide (DMSO), murine and/or bovine products.
21. History of cancer prior to screening (excluding basal cell carcinoma).
22. Acute or chronic infectious disease, including but not limited to human immunodeficiency virus (HIV).
23. Any concurrent disease or condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the study.
24. Treatment and/or an uncompleted follow-up treatment of any investigational. therapy within 6 months before procedure and intent to participate in any other investigational drug or cell therapy study during the 3-year follow-up period of this study.
25. Active participation in other research therapy for cardiovascular repair/regeneration.
26. Prior recipient of stem precursor cell therapy for cardiac repair.
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mesoblast, Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emerson Perin, MD
Role: PRINCIPAL_INVESTIGATOR
Texas Heart Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Gilbert Medical Center
Gilbert, Arizona, United States
University of California, San Diego
La Jolla, California, United States
Minneapolis Heart Institute 920 East 28th St, Suite 300
Minneapolis, Minnesota, United States
UPMC
Pittsburgh, Pennsylvania, United States
Texas Heart Institue
Houston, Texas, United States
Swedish Heart and Vascular Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HF-AB002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.